These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 23956981

  • 1. Concerted action of ANP and dopamine D1-receptor to regulate sodium homeostasis in nephrotic syndrome.
    Fernandes-Cerqueira C, Sampaio-Maia B, Quelhas-Santos J, Moreira-Rodrigues M, Simões-Silva L, Blazquez-Medela AM, Martinez-Salgado C, Lopez-Novoa JM, Pestana M.
    Biomed Res Int; 2013; 2013():397391. PubMed ID: 23956981
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
    Valentin JP, Ying WZ, Sechi LA, Ling KT, Qiu C, Couser WG, Humphreys MH.
    J Am Soc Nephrol; 1996 Apr; 7(4):582-93. PubMed ID: 8724892
    [Abstract] [Full Text] [Related]

  • 3. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome.
    Valentin JP, Qiu C, Muldowney WP, Ying WZ, Gardner DG, Humphreys MH.
    J Clin Invest; 1992 Oct; 90(4):1302-12. PubMed ID: 1328296
    [Abstract] [Full Text] [Related]

  • 4. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
    Ni XP, Safai M, Gardner DG, Humphreys MH.
    Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
    [Abstract] [Full Text] [Related]

  • 5. Restoration of renal responsiveness to atrial natriuretic peptide in experimental nephrotic syndrome by albumin infusion.
    Abassi Z, Weissman I, Karram T, Goltsman I, Hoffman A, Better OS, Winaver J.
    Am J Nephrol; 2013 Apr; 38(4):292-9. PubMed ID: 24080549
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation.
    Ni X, Cheng Y, Cao L, Gardner DG, Humphreys MH.
    J Am Soc Nephrol; 1996 Oct; 7(10):2110-8. PubMed ID: 8915970
    [Abstract] [Full Text] [Related]

  • 7. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
    Ni XP, Safai M, Rishi R, Baylis C, Humphreys MH.
    J Am Soc Nephrol; 2004 May; 15(5):1254-60. PubMed ID: 15100365
    [Abstract] [Full Text] [Related]

  • 8. Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.
    Wilkins MR, Settle SL, Kirk JE, Taylor SA, Moore KP, Unwin RJ.
    Br J Pharmacol; 1992 Sep; 107(1):50-7. PubMed ID: 1330165
    [Abstract] [Full Text] [Related]

  • 9. Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome.
    Sampaio-Maia B, Moreira-Rodrigues M, Serrão P, Pestana M.
    Nephrol Dial Transplant; 2006 Feb; 21(2):314-23. PubMed ID: 16204272
    [Abstract] [Full Text] [Related]

  • 10. Neurohumoral mechanism in the natriuretic action of intracerebroventricular administration of renin.
    Zavala L, Barbella Y, Israel A.
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):39-44. PubMed ID: 15136973
    [Abstract] [Full Text] [Related]

  • 11. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome.
    Plum J, Mirzaian Y, Grabensee B.
    Nephrol Dial Transplant; 1996 Jun; 11(6):1034-42. PubMed ID: 8671965
    [Abstract] [Full Text] [Related]

  • 12. Severe proteinuria without impairment of sodium and volume excretion after puromycin aminonucleoside administration in rats.
    Palluk R, Veress AT, Sonnenberg H.
    Pharmacology; 1989 Jun; 38(4):214-25. PubMed ID: 2526952
    [Abstract] [Full Text] [Related]

  • 13. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B.
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [Abstract] [Full Text] [Related]

  • 14. The effect of atrial natriuretic peptide infusion on renal haemodynamics and plasma lipoproteins in puromycin aminonucleoside nephrosis in rats.
    Radin MJ, McCune SA.
    Clin Exp Pharmacol Physiol; 1993 Apr; 20(4):245-51. PubMed ID: 8485924
    [Abstract] [Full Text] [Related]

  • 15. Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate.
    Jespersen B, Eiskjaer H, Mogensen CE, Sørensen SS, Pedersen EB.
    Nephron; 1995 Apr; 71(1):44-53. PubMed ID: 8538848
    [Abstract] [Full Text] [Related]

  • 16. Atrial Natriuretic Peptide Stimulates Dopamine Tubular Transport by Organic Cation Transporters: A Novel Mechanism to Enhance Renal Sodium Excretion.
    Kouyoumdzian NM, Rukavina Mikusic NL, Kravetz MC, Lee BM, Carranza A, Del Mauro JS, Pandolfo M, Gironacci MM, Gorzalczany S, Toblli JE, Fernández BE, Choi MR.
    PLoS One; 2016 Apr; 11(7):e0157487. PubMed ID: 27392042
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Four-hour atrial natriuretic peptide infusion in conscious rats: effects on urinary volume, sodium, and cyclic GMP.
    Campbell HT, Lightfoot BO, Sklar AH.
    Proc Soc Exp Biol Med; 1988 Dec; 189(3):317-24. PubMed ID: 2849771
    [Abstract] [Full Text] [Related]

  • 19. Role of uroguanylin, a Peptide with natriuretic activity, in rats with experimental nephrotic syndrome.
    Kikuchi M, Fujimoto S, Fukae H, Kinoshita H, Kita T, Nakazato M, Eto T.
    J Am Soc Nephrol; 2005 Feb; 16(2):392-7. PubMed ID: 15590761
    [Abstract] [Full Text] [Related]

  • 20. Atrial natriuretic peptide in renal development.
    Chevalier RL.
    Pediatr Nephrol; 1993 Oct; 7(5):652-6. PubMed ID: 8251341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.